<DOC>
	<DOCNO>NCT02552940</DOCNO>
	<brief_summary>This observational trial evaluate effectiveness , consistency evaluation score , quality life , safety tolerability TCZ administer subcutaneously ( SC ) participant RA daily clinical practice .</brief_summary>
	<brief_title>An Observational Study Evaluate Clinical Effectiveness , Quality Life , Safety Tolerability Tocilizumab ( TCZ ) Patients With Rheumatoid Arthritis ( RA ) Daily Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants naive TCZ receive TCZ SC treatment within 8 week prior enrolment visit include Participants treat physician make decision commence TCZ SC accordance label reimbursement criterion Participants receive TCZ &gt; 8 week prior enrolment visit Participants previously receive TCZ SC Participants receive treatment investigational agent within 4 week start treatment TCZ SC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>